Sugardown (galactomannan) / Boston Scientific - LARVOL DELTA

Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes (clinicaltrials.gov) - P2; N=66; Completed; Sponsor: Boston Therapeutics; Recruiting ➔ Completed

Clinical • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effect of Prolectin-M, a Food Supplement, on SarsCoV2 Viral Copy Numbers: A Proof of Concept Randomized Open Label-controlled Trial (clinicaltrials.gov) - P=N/A; N=10; Not yet recruiting; Sponsor: Composite Interceptive Med Science

Clinical • New trial • Infectious Disease • Novel Coronavirus Disease

Phase 1 Study of the Pharmacology of BTI320 Before High-Glycemic Meals. (PubMed, Clin Pharmacol Drug Dev) - "In study B 2.6 and 5.2 g BTI320 reduced the glycemic index by 10% and 14%, respectively, and led to 14% and 18% decreases in the insulinemic index of the soft drink (P ≤ .05). These 2 studies demonstrated that the consumption of BTI320 before carbohydrate food or sugary beverage significantly reduced postprandial glucose levels and insulin responses to that meal or beverage in a dose-dependent manner."

Journal • P1 data • Cardiovascular • Genetic Disorders • Obesity